Announcements
Trials
Browse
Landscape
Eligibility
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Triple Negative Breast Neoplasms
×
pegfilgrastim
×
Clear all
Filters
3
NCT03036488
2025-10-29
MK-3475-522
Merck Sharp & Dohme LLC
Phase 3
Completed
1,174 enrolled
1 FDA
NCT03197935
2023-10-26
IMpassion031
Hoffmann-La Roche
Phase 3
Completed
333 enrolled
18 charts